Greenwich Lifesciences Inc (GLSI)

$8.32 +0.12 (1.46%)
Market Cap 115.34M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 44,500
Avg Vol 85,650
Day's Range N/A - N/A
Shares Out 13.86M
Stochastic %K 24%
Beta 1.61
Analysts Strong Sell
Price Target $42.00

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 832 819 3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
Gulfoil
Gulfoil Nov. 14 at 10:39 PM
$GLSI amazing execution (from end of 2024 to today cash position Flat!!!)…go f-yourself shorts::::
2 · Reply
Alwaysdiversify
Alwaysdiversify Nov. 14 at 10:30 PM
$GLSI I see that cash continues to hover around $4 million. Management judiciously using the ATM only to bridge the gap until dropping big news. Just my opinion, but if they were not strongly bullish on the prospects for IA, then we would have seen them drop an offering (that is, not fully purchased by Snehal again) by now.
0 · Reply
suspendFlow
suspendFlow Nov. 14 at 10:28 PM
$GLSI Stock based compensation more than doubled (?) They need money. I am guessing some private placement will come to pay for the gap until interim and they do another offering if interim pumps. If no pump, goodnight sweet prince.
0 · Reply
Sanibelspeaks
Sanibelspeaks Nov. 14 at 6:01 PM
$GLSI happy to report my friends. I’m now officially back in!! just bought.- I don’t think now I would sell until THE DAY - too risky to get out and miss it
0 · Reply
jm4
jm4 Nov. 14 at 4:20 PM
$GLSI Notable deal $9.2B deal in infectious disease category for PhaseII but $MRK still needs to address Keytruda cliff. Possibly Flamingo...🦩 https://content.seleritycorp.com/hosted2/assets/www/DwiB2GaxFMTzNufvImAKqtUWBErIU0WusB8iN_SeRhg
1 · Reply
Rolltide2020
Rolltide2020 Nov. 14 at 4:13 PM
$GLSI Down to 4,000 and cost to borrow up to 24.64 👀
1 · Reply
Akcash
Akcash Nov. 14 at 2:57 PM
$GLSI I'm long here. But nothing is over til it's over. Shorts are here because majority of phase 3 trials fail. Yes this one is maybe different (I am long and believer). But manage your risk accordingly
1 · Reply
Alwaysdiversify
Alwaysdiversify Nov. 14 at 2:02 PM
$GLSI Shorts are really scraping the bottom of the barrel. Shares available to borrow as of a few minutes ago were down to just 6,000. Absent an offering, how the heck do they expect to reasonably cover the 1.35 million shares shorted? Even more so in the even of a drop of big positive news. I'd sure like to know who actually has the cajones to short such volume at this stage of the game. Ummmm........
1 · Reply
hkjj
hkjj Nov. 14 at 12:58 PM
$GLSI Soon one day, we will celebrate as same as today diamond holders of $CDTX
1 · Reply
mshah1615
mshah1615 Nov. 14 at 11:59 AM
$GLSI
0 · Reply
Latest News on GLSI
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 9, 2025, 6:00 AM EDT - 5 weeks ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 6 weeks ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 6 weeks ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 3 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 8 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 8 months ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 10 months ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 10 months ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 10 months ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 10 months ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 10 months ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 10 months ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Jun 26, 2024, 2:05 PM EDT - 1 year ago

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 3 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Aug 3, 2022, 8:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Jul 28, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Jul 12, 2022, 1:18 PM EDT - 3 years ago

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Jul 12, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Jul 11, 2022, 4:15 PM EDT - 3 years ago

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

May 23, 2022, 7:00 AM EDT - 3 years ago

Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

May 23, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences: A First Look

May 19, 2022, 11:12 AM EDT - 3 years ago

Greenwich LifeSciences: A First Look

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Apr 21, 2022, 8:55 AM EDT - 3 years ago

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Apr 20, 2022, 6:10 AM EDT - 3 years ago

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Apr 19, 2022, 6:21 AM EDT - 3 years ago

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Mar 3, 2022, 9:19 AM EST - 4 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Feb 3, 2022, 6:00 AM EST - 4 years ago

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Feb 1, 2022, 6:00 AM EST - 4 years ago

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Gulfoil
Gulfoil Nov. 14 at 10:39 PM
$GLSI amazing execution (from end of 2024 to today cash position Flat!!!)…go f-yourself shorts::::
2 · Reply
Alwaysdiversify
Alwaysdiversify Nov. 14 at 10:30 PM
$GLSI I see that cash continues to hover around $4 million. Management judiciously using the ATM only to bridge the gap until dropping big news. Just my opinion, but if they were not strongly bullish on the prospects for IA, then we would have seen them drop an offering (that is, not fully purchased by Snehal again) by now.
0 · Reply
suspendFlow
suspendFlow Nov. 14 at 10:28 PM
$GLSI Stock based compensation more than doubled (?) They need money. I am guessing some private placement will come to pay for the gap until interim and they do another offering if interim pumps. If no pump, goodnight sweet prince.
0 · Reply
Sanibelspeaks
Sanibelspeaks Nov. 14 at 6:01 PM
$GLSI happy to report my friends. I’m now officially back in!! just bought.- I don’t think now I would sell until THE DAY - too risky to get out and miss it
0 · Reply
jm4
jm4 Nov. 14 at 4:20 PM
$GLSI Notable deal $9.2B deal in infectious disease category for PhaseII but $MRK still needs to address Keytruda cliff. Possibly Flamingo...🦩 https://content.seleritycorp.com/hosted2/assets/www/DwiB2GaxFMTzNufvImAKqtUWBErIU0WusB8iN_SeRhg
1 · Reply
Rolltide2020
Rolltide2020 Nov. 14 at 4:13 PM
$GLSI Down to 4,000 and cost to borrow up to 24.64 👀
1 · Reply
Akcash
Akcash Nov. 14 at 2:57 PM
$GLSI I'm long here. But nothing is over til it's over. Shorts are here because majority of phase 3 trials fail. Yes this one is maybe different (I am long and believer). But manage your risk accordingly
1 · Reply
Alwaysdiversify
Alwaysdiversify Nov. 14 at 2:02 PM
$GLSI Shorts are really scraping the bottom of the barrel. Shares available to borrow as of a few minutes ago were down to just 6,000. Absent an offering, how the heck do they expect to reasonably cover the 1.35 million shares shorted? Even more so in the even of a drop of big positive news. I'd sure like to know who actually has the cajones to short such volume at this stage of the game. Ummmm........
1 · Reply
hkjj
hkjj Nov. 14 at 12:58 PM
$GLSI Soon one day, we will celebrate as same as today diamond holders of $CDTX
1 · Reply
mshah1615
mshah1615 Nov. 14 at 11:59 AM
$GLSI
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Nov. 13 at 9:40 PM
$GLSI is $8 going to be 2021´s $5?It is getting harder and harder to get shares. Price is tightening in a falling wedge and looks primed for a breakout to $11 handle. Very solid price action while the rest of the market took a heavy beating!
0 · Reply
Toontje1
Toontje1 Nov. 13 at 8:31 PM
$GLSI Ready to buy more next year. when can we expect some good news?
2 · Reply
Nherring
Nherring Nov. 13 at 1:48 PM
$GLSI could earnings tmrw release any big news? thoughts
1 · Reply
Alwaysdiversify
Alwaysdiversify Nov. 13 at 1:35 PM
$GLSI This stock sure trades as if the vast majority of the official float of 6.5 million shares is already locked up. To what extent, I'd sure like to know. If I had to guess, I'd say at least half of that float is in the hands of bulls that are not looking to flip this for pennies. Thoughts??
2 · Reply
mshah1615
mshah1615 Nov. 13 at 11:30 AM
$GLSI I am Just Wondering Why No one see What we see on GLSI All the Postive News Insider Buying Stock(No Single Share Sold) Fast Approval From FDA 150 Clinical Site Three to Four Months ago some interviews Very Tiny Float to Trade I am not experts on How many events ( So i am not going comment) But what i read here not negative plz let me know your Inputs
2 · Reply
DerekVtx
DerekVtx Nov. 12 at 8:27 PM
Sold all of my position of $GLSI month ago for approx 11.50 per share and my $NVAX four approx 8 a share moved it all over to $MLTX for the bounce. It hasn't bounced back yet (Still down 80%) but from $6.50 to $12.83 ive nearly doubled my money. I will be back to $GLSI but gonna wait it out a bit longer yet, GLSI could still have a ways to bleed out and i wanna get as many shares as possible when I do buy back..
1 · Reply
hainahola
hainahola Nov. 12 at 8:20 PM
$GLSI when is er?
0 · Reply
msgbrdinfo
msgbrdinfo Nov. 12 at 3:34 PM
$GLSI Snehal is gonna be a billionaire. I think his buying this late in the Phase 3 trial is throwing a bone to retail investors. What better way to exude confidence in Flamingo-01/GLSI-100 then to buy shares like he has?
1 · Reply
hkjj
hkjj Nov. 12 at 2:54 PM
$GLSI https://x.com/hongkonger2022/status/1988609626850705452?s=46&t=tQ7QfVxJa42d2SUgS6Oyxw
0 · Reply
Rolltide2020
Rolltide2020 Nov. 12 at 2:16 PM
$GLSI I would argue that this trial is double-blinded and that even Snehal does not know when IA will occur.....which means he could buy shares whenever he wants without conflict (assuming he doesn't really know). I personally don't think we will get IA until closer to the lock up date at the end of March, but the fact that he is buying doesn't necessarily mean news couldn't come sooner.
2 · Reply
jm4
jm4 Nov. 12 at 1:44 PM
$GLSI
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Nov. 12 at 1:10 PM
$GLSI CEO purchased 10,600 shares at $8.43 for a total of $89,358. Patel Snehal now owns 5,583,502 shares. https://ceo-buys.com
0 · Reply